"Purpose
RAF inhibitors are effective against melanomas with BRAF
V600E mutations but may induce keratoacanthomas (KAs) and cutaneous
squamous cell carcinomas (cSCCs). The potential of these
agents to promote secondary malignancies is
concerning. We analyzed cSCC and KA lesions for genetic mutations in an
attempt
to identify an underlying mechanism for their
formation.
Four international centers contributed 237 KA or cSCC tumor samples from patients receiving an RAF inhibitor (either vemurafenib or sorafenib; n = 19) or immunosuppression therapy (n = 53) or tumors that developed spontaneously (n = 165)........."